Genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.
Both genes and environmental factors play a role in the occurrence of allergic diseases, according to a new study in Translational Pediatrics.
Genetics and environment both influence allergy risk, but environmental factors play a stronger role in the progression of allergic disease.
Image credit: pingpao - stock.adobe.com
“Our prospective study found that a family history of allergy had no effects on [atopic dermatitis], allergic rhinitis, and wheezing between the twin groups,” wrote investigators, led by Jing Wang, from the department of pediatrics at Qilu Hospital of Shandong University in China. “Instead, environmental factors influenced the development of allergic diseases.”
The “allergic march” begins with infantile atopic dermatitis at 1 to 3 months of age. This is typically linked to food allergies, which progress during the first year of life. A prior birth cohort study found that infantile atopic dermatitis is associated with the development of asthma and rhinitis by 7 years old.
Investigators sought to understand the factors leading to the development of allergic diseases. They conducted a prospective clinical study of 80 identical and fraternal twins aged ≤ 4 years to identify the potential differences in environmental and genetic factors that contribute to allergy progression; data was collected via a 48-month questionnaire. In this study, identical and fraternal twins had similar rates of 60% to 80% for inhalation allergens at 2 years old.
The study reported no statistically significant differences between identical and fraternal twins in terms of gender, gestational age, history of asphyxia, feeding methods, and birth weight.
Compared with fraternal twins, identical twins had a significantly greater incidence of atopic dermatitis (100% vs 17%; P < .001), rhinitis (100% vs 20%; P < .001), and food allergy (100% vs 27%; P < .001). Wheezing had no significant difference in identical vs fraternal twins (80% vs 83%; P > .05).
Wang and colleagues discovered that, from 6 months to 48 months, the incidence of atopic dermatitis decreased (80% to 16.7% in identical twins; 50% to 26% in fraternal twins), and the incidence of rhinitis (5% to 16.7% in identical twins; 3% to 44% in fraternal twins) and wheezing (10% to 41.7% in identical twins; 0% to 26% in fraternal twins) increased.
Additionally, identical twins had a significantly greater consistency of inhaled allergens (100% vs 80%; P < .001; effect size, 0.619) and positive food allergens (86% vs 57%; P < .001; effect size, 0.597).
Investigators also analyzed the incidence of allergic diseases based on specific factors. For instance, among identical twins, they found atopic dermatitis and wheezing were more frequent in those who were male, had a birth weight of < 2500 g, and had another sibling (P < .05). Rhinitis in identical twins was more frequent among those who lived in a bungalow-style home, had pets, and had carpeting (P < .05).
As for fraternal twins, atopic dermatitis was more frequent in those who were born < 37 weeks gestation and had flowers or plants in the house (P < .05). Rhinitis in fraternal twins was more frequent in those born < 37 weeks gestation, with a history of neonatal asphyxia, and who lived in a smoking household (P < .05). Wheezing in fraternal twins was more frequent in those born < 37 weeks gestation, with a history of neonatal asphyxia, with central heating, and who lived in a smoking household (P < .05).
“The occurrence of allergic diseases in children is not only related to genes, but also influenced by environmental factors, and the influencing factors of allergic diseases in identical and fraternal twins are not the same,” investigators concluded.
References
Fixed-Duration Epcoritamab Is Active, Safe in Older Patients With Newly Diagnosed LBCL
December 17th 2024Epcoritamab-bysp showed a 69% objective response rate and 62% complete response rate in older patients with large B-cell lymphoma who were ineligible for anthracycline-based therapy.
Read More
Patients With Higher Disease Burden, Lower HRQoL More Likely to Switch to Biologic Therapies
December 10th 2024Researchers found patients reporting greater disease burden and lower health-related quality of life (HRQoL) are more likely to switch to biologic therapies, regardless of clinician-rated disease severity.
Read More
FDA Approves Sixth Ustekinumab Biosimilar, Yesintek
December 2nd 2024The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with various immunology conditions, including psoriatic arthritis and inflammatory bowel disease.
Read More
Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation
December 1st 2024Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.
Read More